Kringle Pharma, Inc. (4884.T)
JPY 814.0
(-0.73%)
JPY 814.0
(-0.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 69.25 Million JPY | -77.18% |
| 2022 | 303.41 Million JPY | 39.08% |
| 2021 | 218.15 Million JPY | -53.35% |
| 2020 | 467.61 Million JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 18.46 Million JPY | -24.13% |
| 2024 Q1 | 18.69 Million JPY | 5.47% |
| 2024 Q2 | 24.33 Million JPY | 30.22% |
| 2023 Q4 | 17.72 Million JPY | 3.17% |
| 2023 FY | 69.25 Million JPY | -77.18% |
| 2023 Q3 | 17.17 Million JPY | 1.11% |
| 2023 Q1 | 17 Million JPY | -91.12% |
| 2023 Q2 | 16.98 Million JPY | -0.07% |
| 2022 FY | 303.41 Million JPY | 39.08% |
| 2022 Q4 | 191.34 Million JPY | 0.0% |
| 2021 FY | 218.15 Million JPY | -53.35% |
| 2020 FY | 467.61 Million JPY | 0.0% |
| 2019 FY | - JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 96.319% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 13.767% |
| GNI Group Ltd. | 22.43 Billion JPY | 99.691% |
| Linical Co., Ltd. | 3.77 Billion JPY | 98.167% |
| Trans Genic Inc. | 2.24 Billion JPY | 96.921% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 29.518% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 97.21% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 94.643% |
| AnGes, Inc. | -3.06 Billion JPY | 102.259% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 138.966% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 99.283% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 86.613% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 37.588% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 95.226% |
| CanBas Co., Ltd. | -984 Million JPY | 107.038% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 82.321% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 95.819% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 82.626% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 93.337% |
| PeptiDream Inc. | 17.21 Billion JPY | 99.598% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -126.27% |
| Ribomic Inc. | -10.5 Million JPY | 759.398% |
| SanBio Company Limited | -14.5 Million JPY | 577.454% |
| Healios K.K. | 108 Million JPY | 35.88% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 20407.918% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 217.281% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 4680.026% |
| StemRIM | -44.34 Million JPY | 256.148% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 97.826% |
| FunPep Company Limited | -680.28 Million JPY | 110.18% |
| Stella Pharma Corporation | 217.29 Million JPY | 68.131% |
| TMS Co., Ltd. | -6.95 Million JPY | 1096.403% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 77.985% |
| Cuorips Inc. | 9.63 Million JPY | -619.032% |
| K Pharma,Inc. | 910 Million JPY | 92.39% |
| Takara Bio Inc. | 25.45 Billion JPY | 99.728% |
| ReproCELL Incorporated | 1.1 Billion JPY | 93.731% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 94.205% |
| StemCell Institute Inc. | 1.57 Billion JPY | 95.606% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 95.845% |
| CellSeed Inc. | 107.15 Million JPY | 35.374% |